ERBB2 and neoplasm: Some studies demonstrate the induction of HER2 downregulation in HER2-positive cancer cells with the immune effector cells’ engagement, revealing a new function of immune cells in trastuzumab-mediated antitumor efficacy and probably representing a novel mechanism of action of trastuzumab, predicting active immune effector cells’ recruitment in the tumor microenvironment [34].